CNS and oncology appear prime targets for Proteus and Otsuka's 'digital medicines'
This article was originally published in Scrip
In another sign of the blurring boundaries between therapeutics and medical technology, Otsuka Pharmaceutical has put down its marker in the area of drug compliance management, linking up with Proteus Digital Health for the joint development and commercialisation of "digital medicines".
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.